Celularity warned on Nasdaq $1 minimum bid rule
Rhea-AI Filing Summary
Celularity Inc. reported that on July 23, 2026 it received a notice from the Nasdaq Stock Market stating its Class A common stock no longer meets the $1.00 per share minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), after the closing bid stayed below that level for 30 consecutive business days.
The notice does not immediately affect trading of CELU shares on the Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(3)(A), Celularity has 180 calendar days, until January 19, 2027, for its closing bid price to be at least $1.00 for a minimum of 10 consecutive business days to regain compliance. The company plans to monitor its share price and evaluate options, while cautioning there is no assurance it will regain compliance, obtain a second 180-day grace period, or maintain compliance with other Nasdaq listing requirements.
Positive
- None.
Negative
- Nasdaq minimum bid deficiency: Celularity received notice that its Class A common stock closed below $1.00 for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk if compliance is not restored by January 19, 2027.
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rule 5450(a)(1) regulatory
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
minimum bid price requirement regulatory
Nasdaq Capital Market regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq notice did Celularity (CELU) receive on July 23, 2026?
How long does Celularity (CELU) have to regain Nasdaq bid-price compliance?
Does the Nasdaq notice immediately affect Celularity (CELU) trading on Nasdaq?
What happens if Celularity (CELU) does not regain compliance by January 19, 2027?
Can Celularity (CELU) be sure it will stay listed on Nasdaq?
AI-generated analysis. How Rhea-AI works. Not financial advice.